An analysis of the clinical utility of the Hematotox-Score demonstrated the tool is predictive of hematologic toxicity in patients undergoing CAR-T therapy, but is not predictive of mortality.

Targeted, culturally adapted clinical and public health interventions are needed to narrow disparities in cancer mortality,” researchers concluded.

More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation therapy, according to researchers.

HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...